Изучение механизмов АНТИ-ВИЧ активности производных высших тритерпенов и хинонов

Список литературы

1. Мазин А.В., Кузноделов К. Д., Краев А. С. и др. Методы молекулярной генетики и генной инженерии. М.: «Наука». 1990
2. Маниатис Т., Фрт Э., Сэмбрук Дж. Молекулярное клонирование. М.: «Мир». 1984
3. Карамов Э.В., Богомолов Б. П., Жданов В. М. Обзор центров, сотрудничающих с ВОЗ по вирусным инфекциям. М. 1986. С.4−7
4. Островский В.А. Синтетические лекарственные средства против ВИЧ/СПИД. 1999. Соровский образовательный журнал. № 9. С.44−51
5. Петренко Н. И, Петухова В. З., Шатров М. М Синтетические трансформации высших терпеноидов V. Синтез и спектральные данные производных глицирретовой кислоты, содержащих аминокислотные фрагменты. 2000. Журнал органической химии. Т.36(7). С. 1013−1026
6. Плясунова О.А., Егоричева И. Н., Федюк Н. В. Изучение анти-ВИЧ активности (3-глицирризиновой кислоты. 1992. Вопросы вирусологии. Т.37(5−6). С.235−238
7. Покровский А.Г., Плясунова О. А., Гашникова Н. М., Мамаева О. А., Федюк Н. В. Хронически инфицированная ВИЧ-1 культура моноцитов человека U937 как модель для оценки эффективности анти-ВИЧ препаратов. 2001. Вопросы вирусологии. № 6. С. 38−42
8. Покровский А.Г., Федюк Н. В., Абдуллаев С. М., Болтина Л. А., Толстиков Г. А. Индуктор гамма интерферона// Заявка на патент РФ № 2 003 134 868 от 01.12.03
9. Розовская Т.А., Белогуров А. А., Лукин М. А., Чернов Д. Н., Куханова М. К., Бибилишвили Р. Ш. Обратная транскриптаза вируса иммунодефицита человека: выделение и субстратная специфичность. 1993. Молекулярная биология. Т.27. С.618−629
10. Руднева ИА., Карамов Э. В., Горчакова ТА. и др. Штамм перевиваемых клеток моноцитов человека продуцент вируса иммунодефицита человека 1 типа. Патент РФ № 1 554 370, выдан 19.03.1993
11. Семенова Е.А., Плясунова OA., Петренко Н. И., Узенкова Н. В., Шулъц Э. Э., Толстиков ГА., Покровский А. Г. Ингибирование рекомбинантной интегразы ВИЧ-1 производными высших терпеноидов. 2003. Доклады Академии Наук. Т.391(4). С. 218−220
12. Толстиков Г. А., Шулъц Э. Э., Болтина Л. А., Толстикова Т. Г. Солодка. Неиспользуемые возможности здравоохранения России. Химия в интересах устойчивого развития. 1997. Т.5. С.57−73
13. Толстиков Г. А., Болтина Л. А., Шулъц Э. Э., Покровский А. Г. Глицирризиновая кислота. 1997. Биоорганическая химия. Т.23(7). С. 691−709
14. Толстиков Г. А., Шулъц Э. Э., Сафарова Г. М., С.пирихин Л. В. Получение 2-фурилцикланонов диеновым синтезом. 1990. Журнал органической химии. Т. 28(6). С. 1283−1296
15. Шульц Э.Э., Петрова Т. Н., Шакиров М. М., Черняк Е. И., Гранкина В. П., То.чсткков Г. А. Фенольные соединения подземной части солодки уральской (Glycyrrhiza uralensis Fisch.) сибирских популяций. 2000. Химия в интересах устойчивого развития. Т.8. С.453−457
16. Уэбб Л. Ингибиторы ферментов и метаболизма. М: Мир. 1966. С. 864
17. Хесин Р. М. Непостоянство генома. М.: «Наука». 1984. С.237
18. Ahmad N., Venkatesan S. Nef protein of HIV-1 is a transcriptional repressor of HIV-1 LTR. 1988. Science. Y.241. P.1481−1485
19. Akihisa T, Ogihara J, Kato J, Yasukawa K, Ukiya M, Yamanouchi S, Oishi K. Inhibitory effects of triterpenoids and sterols on human immunodeficiency virus-1 reverse transcriptase. 2001. Lipids. V.36(5). P.507−512
20. Bagasra O., Whittle P., Heins В., Pomerantz R.J. Anti-human immunodeficiency virus type 1 activity of sulfated monosaccharides: comparison with sulfated polysaccharides and other polyions. 1991. J. Infect. Dis. V.164(6). P.1082−1090
21. Baltina LA. Chemical modification of glycyrrhizic acid as a route to new bioactive compounds for medicine. 2003. Curr. Med. Chem. V.10(2). P. 155−171
22. Balzarmi J., De Clercq E., Serafinowski P., Dorlcmd E., Harrap K.R. Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives. 1992. J. Med. Chem. V.35(24). P.4576−83
23. Bean P. The use of alternative medicine in the treatment of hepatitis C. 2002. Am. Clin. Lab. V.21(4). P. 19−21
24. Berube, P., Barbeau, B., Cantin, R, Sekaly, R.-P., ТгетЫауМ- Repression of Human Immunodeficiency Virus Type 1 LTR-driven gene expression by binding of the virus to its primary cellular receptor, the CD4 molecule. 1996. J. Virol. V.6. P.4009−4016
25. В irk В., Sonnerborg A. Variations in HIV-1 pol gene associated with reduced sensitivity to anti-retroviral drugs in treatment-naive patients. 1998. AIDS. V.12. P.2369−2375
26. Boyer P.L., Ferris A.L., Hughes S.H. Mutational analysis of the fingers domein of HIV-1 reverse transcriptase. 1992. J. Virol. V.66. 7533−7537
27. Boyer P.L., Ferris A.L., Clark A. Mutational analysis of the fingers and palm subdomeins of HIV-1 reverse transcriptase. 1994. J. Mol. Biol. V. 243. P.472−483
28. Bukrinsky, M, Sharova, N., Stevenson, M. Human Immunodeficiency Virus Type 1 2-LTR circles reside in a nucleoprotein complex which is different from the preintegration complex. 1993. J. Virol. V.ll. P.6863−6865
29. Caputo, A., Grossi, M., Rossi, C" Campion, D., Balboni, PJ. The tat gene and protein of the Human Immunodeficiency Virus Type 1. 1995. Microbiologica. V.18. P. 87-П0
30. Chang, L.J., Zhang, С. Infection and replication of Tat" HIV: genetic analyses of LTR and tat mutations in primary and long-term human lymphoid cells. 1995. Virology. V.211. P.157−169
31. A3. С hang W.S., Yan G.F., Chiang H.С. Inhibitory effects of phenolic carboxylic acid analogues on xanthine oxidase. 1995. Anticancer Res. V.15(5). P.2097−2100
32. Chen I.J., Neamati N., MacKerell A.D. Jr. S tincture-based inhibitor design targeting HIV-1 integrase. 2002. Cuit. Drug Targets Infect. Disord. V.2(3). P.217−234
33. Cinatl J., Morgenstern В., Bauer G., Chandra .P, Rabenau H., Doerr H.W. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. 2003. Lancet. V.361(9374). P.2045−2046
34. Cowan M.M. Plant products as antimicrobial agents. 1999. Clin. Microbiol. Rev. V.12. P.564−582
35. C.rance J.M., Scaramozzino N., Jouan A., Garin D. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. 2003. Antiviral Res. V.58(l). P.73−79
36. Cullen, B.R. Mechanism of Action of Regulatory Proteins Encoded by Complex Retroviruses. 1992. Microbiological Reviews. V.9. P.375−394
37. Dharmaratne H.R., Tan G.T., Marasinghe G.P., Pezzuto J.M. Inhibition of HIV-1 reverse transcriptase and HIV-1 replication by Calophyllum coumarins and xanthones. 2002. Planta Med. V.68(l). P.86−87
38. Darrick S.H., Kim L., Chen Z, Nguyen V.T., Pezzuto J., Qiu S., Lu Z.Z. A concise semi-synthetic approach to betulinic acid from betulin. 1997. Synth. Commun. V. 27(9). P.1607−1612
39. Debyser Z., Cherepanov P., Van Maele В., De C. lercq E., Wit>rouw M. In search of authentic inhibitors of HIV-1 integration. 2002. Antivir. Chem. Chemother. V.13(l). P.1−15
40. De S.K., Marsh J. W. HIV-1 Nef Inhibits a common activation pathway in NIH-3T3 cells. 1994. J. Biol. Chem. V.269(9). P.6656−6660
41. De Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance. 1996. Medical virology. V.6. P.97−110
42. De Clercq E. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) ii the therapy of HIV-1 infection. 1999. Farmaco. V.54(l-2). P.26−45
43. De Clercq E. The emerging role of fusion inhibitors in HIV infection. 1999. Drugs R D. V.2(5). P.321−331
44. De Clercq E. Current lead natural products for the chemotherapy of humai immunodeficiency virus (HIV) infection. 2000. Med. Res. Rev. V.20(5). P.323−349.
45. De Clercq E. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. 2000. Mol. Pharmacol. V.57(5). P.833−839
46. De Clercq E., Schols D. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists. 2001. Antivir. Chem. Chemother. V.l. P. 19−31
47. De Clercq E. New anti-HIV agents and targets. 2002. Med. Res. Rev. V.22(6). P.531−565.
48. Dumaz N., Milne D.M., Meek D.W. Protein kinase CK1 is a p53-threonine 18 kinase which requires prior phosphorylation of serine 15. 1999. FEBS Lett. V.463(3). P.312−316
49. EsnoufR., Ren J., Ross C., Jones Y., Stammers D., Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. 1995. Nat. Strict Biol. V.2(4). P.303−308
50. Essex M. Human immunodeficiency viruses in the developing world. 1999. Ad. Virus. Res. V.53. P.71−88юз
51. Farnei Ch., Haseltine W.A. Integration of humah immunodeficiency vims type 1 DMA in vitro. 1990. Proc. Natl. Acad. Sci. USA. V.81(6). P.4164−4168
52. Farnei Ch., Haseltine W.A. Circulisation of humah immunodeficiency vims type 1 DNA in vitro. 1991. J. Virol. V.65. P.6942−695
53. FreedE.O. HIV-1 replication. 2001. Somat. Cell. Mol. Genet. V.26(l-6). P.13−33
54. Fujisawa Y., Sakamoto M., Matsushita M., Fujita Т., Nishioka K. Glycyrrhizin inhibits the lytic pathway of complement—possible mechanism of its antiinflammatory effect on liver cells in viral hepatitis. 2000. Microbiol. Immunol. V.44(9). P.799−804
55. Furman P.A., Fyfe J.A., SaintClair M.H. Posphorylation of 3'-azido-3--deoxythymidine and selective interaction of the 5'-triphosphate with HIV-1 reverse transcriptase. 1986. Proc. Natl. Acad. Sci. V.83. P.8333−8337
56. Garg R., Gupta S.P., Gao H., Babu M.S., Debnath A.K., Hansch C. Comparative Quantitative Stmcturemrnus sign Activity Relationship Studies on Anti-HIV Drugs. 1999. Chem. Reviews. V. 99(12). P. 3525−3601
57. Hatano Т., Yasuhara Т., Miyamoto K., Okuda T. Anti-human immunodeficiency virus phenolics from licorice. 1988. Chem. Pharm. Bull. V.36(6). P.2286−2288
58. Hatomi M., Tanigawa K., Fujihara M., Ito J., Yanahira S., Ohtsuki K. Characterization of bovine and human lactoferrins as glycyrrhizin-binding proteins and their phosphorylation in vitro by casein kinase II. 2000. Biol. Pharm. Bull. V.23. P.1167−1172
59. Hattori Т., Ikematsu S., Koito A., Matsushita S., Maeda Y., Hada M., Fujimaki M., Takalsuki K. Preliminary evidence for inhibitory effect of glycyrrhizin on HIV replication in patients with AIDS. 1989. Antiviral Res. V.5−6. P.255−261
60. Harrich D., Ulich C., Gaynor R.B. A critical role for the TAR element in promoting efficient Human Immunodeficiency Virus Type 1 Reverse transcription. 1996. J. Virol. V.6. P.4017−4027
61. Havsteen B. The biochemistry and medical significance of the flavonoids. Pharmacology and Therapeutics. 2002. V.96(2−3). P.67−202
62. Higuchi H., Mori К., Kaio A., Ohkuma Т., Endo Т., Kaji H. Antiretroviral activities of anthraquinones and their inhibitory effects on reverse transcriptase. 1991. Antiviral. Res. V. 15(3). P. 205−216
63. Holz-Smith S.L., Sun C, Jin L, Matthews T.J., Lee K.-H., C. hen С H. Role of Human Immunodeficiency Virus (HIV) Type 1 Envelope in the Anti-HIV Activity of the Betulinic Acid Derivative IC9564. 2001. Antimicrob. Agents Chemother. V. 45. P. 60−66
64. Hofmann K, Bucher P., Falquet. L., Bairoch A. The PROSITE database, its status in 1999. 1999. Nucleic Acids Res. V.27. P.215−219.
65. Howcroft Т.К., Palmer L.A., Brown J., Rellahan В., Kashanchi F. HIV Tat represses transcription through Spl-like elements in the basal promoter. 1995. Immunity. V.3. P.127−138
66. Huang Y., Zhang L., Ho L. Biological Characterization of nef in Long Term Survivors of Human Immunodeficiency Virus Type 1 Infection. 1995. J. Virol. V.69(12). P.8142−8146
67. Huang L., Chen C.H. Molecular targets of anti-HIV-1 triterpenes. 2002. Curr. Drug Targets Infect. Disord. V.2(l). P.33−36
68. Huang X., Miller W. A time-efficient, linear-space local similarity algorithm. 1991. Advances in Applied Mathematics. V. 12. P.337−357
69. Jacobo-Molina A., Ding J., Nanni R.G. Ciystal structure of of HIV-1 reverse transcriptase complexed with double-stranded DNA at 3.0 a resolution shows bent DNA. 1993. Proc. Natl. Acad. Science. V.92. P. 1222- 1226
70. Johnson V. Combination therapy for HIV-1 infection-overview: preclinical and clinical analysis of antiretroviral combinations. 1996. Antiviral Res. V.29. P.35−39
71. Jonckheere H, Anne J, De Clercq E. The HIV-1 reverse transcription (RT) process as target for RT inhibitors. 2000. Med. Res. Rev. V.20(2). P. 129−154
72. Kah-aichev Z, Walder R., Garzaro D. Anti-HIV activity of extracts from Calendula officinalis flowers. 1997. Biomed. Pharmacother. V.51(4). P. 176−80
73. Kashiwada Y., Hashimoto F., C. osentino L.M., Chen C.-H., Garrett P.E., Lee K.H. Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. 1996. J. Med. Chem. V. 39. P. 1016−1017
74. Katz R.A., Skalka A.M. The retroviral enzymes. 1994. Annu. Rev. Biochem. V.63. P.133−173
75. Klimkait. Т., Strebel K., Hoggan M.D., Martin M.A., Orenstein J.M. The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. 1990. J. Virol. V.64(2). P.621−629
76. Kuritzkes D.R. Resistance to protease inhibitors. 2002. J. HIV Ther. V.7(4). P.87−91
77. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. 1970. Nature. V.2. P.680−685
78. Lau A.F., Siedlecki J., Anleitner J., Patterson G.M., C. aplan F.R., Moore RE. Inhibition of reverse transcriptase activity by extracts of cultured blue-green algae (cyanophyta). 1993. PlantaMed. V.59(2). P.148−151
79. Lee-Huang S., Huang P.L., Nara P.L., Chen H.C., Kung H.F., Huang P., Huang H.I., Huang P.L. MAP 30: a new inhibitor of HIV-1 infection and replication. 1990. FEBS Lett. V.272(l-2). P. 12−18
80. Levy J. A. Pathogenesis of Human Immunodeficiency Virus Infection. 1993. Microbiological Reviews. V. 11. P. 183−289
81. Li В.О., Fu Т., Dongyan Y., Mikovils J.A., Ruscetti F.W., Wang JM. Flavonoid baicalin inhibits HIV-1 infection at the level of viral entty. 2000. Biochem. Biophys. Res. Commun. V.276(2). P.534−538
82. Lifrak S. Retroviral reverse transcriptase. Molecular biology Intellegence Unit. 1996. P.208
83. Mahmood N., Pizza C., Aquino R., De Tommasi N., Piacente S., Colman S., Burke A., Hay A.J. Inhibition of HIV infection by flavanoids. 1993. Antiviral Res. V.22(2−3). P.189−199
84. Majumdar C., Stein C.A., Cohen J.S., BroderS., Wilson S.H. Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide. 1989. Biochemistry. V.28. P. 1340−1346
85. Maldarelh F., Sato H., Berthold E., Orenstain J., Martin M.A. Rapid induction of apoptosis by cell-to-cell transmission of Human Immunodeficiency Vims Type 1. 1995. J. Virol. V.69(10). P.6457−6465
86. Mdisuse I.Т., him Y.A., Hattori M, Correa M" Gupta M.P. A search for anti-viral properties in Panamanian medicinal plants. The effects on HIV and its essential enzymes. 1999. J. Ethnopharmacol. V.64(l). P. 15−22
87. Merluzzi V.J., Hargra>e K.D., Labadia M., Grozinger K., Skoog M., Wu J.C., Shih C.K., Eckner K, Hattox S., Adams J. Inhibition of HIV-1 replication by a noimucleoside reverse transcriptase inhibitor. 1990. Science. V.250(4986). P. 14 111 413
88. Min B.S., Nakamura N., Miyashiro H., Kim Y.H., Hattori M. Inhibition of human immunodeficiency vims type 1 reverse transcriptase and ribonuclease H activities by constituents of Juglans mandshurica. 2000. Chem. Pharm. Bull. V.48(2). P. 194−200
89. Mlinaric A., Kreft S., UmekA., Strukelj B. Screening of selected plant extracts for in vitro inhibitory activity on HIV-1 reverse transcriptase (HIV-1 RT). 2000. Pharmazie. V.55(l). P.75−77
90. Morin M.J. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. 2000. Oncogene. V. 19(56). P.6574−6583
91. Motti C., NuzzoM., MeolaA., Galfre G., Felici F., Cortese R., Nicosia A., Mcmaci P. Recognition by human sera and immunogenicity of HBsAg mimitopes selected from an M13 phage display library. 1994. Gene. V. 146. P. 191−198
92. Mui Ph. W., Jacober S.P., Hargrave K.D., Adams J., Ciystal structure of nevirapine, a non-nucleoside inhibitor of HIV-1 reverse transcriptase, and computational alignment with a structurally diverse inhibitor. 1992. J. Med. Chem. V.35. P.201−202
93. Nakashima H., Murakami Т., Yamamoto N., Sakagami H., Tanuma S., Ha tan о Т., Yoshida Т., Okuda Т. Inhibition of human immunodeficiency viral replication by tannins and related compounds. 1992. Antiviral Res. V.18(l). P.91−103
94. Nair V. HIV integrase as a target for antiviral chemotherapy. 2002. Rev. Med. Virol. V. 12(3). P. 179−193
95. Neer E.J., Clapham D.E. Roles of G protein subunits in transmembrane signaling. 1988. Nature. V.333. P.129−130
96. Olukoga A., Donaldson D. Liquorice and its health implications. 2000. J. R. Soc. Health. V. 120(2). P.83−89
97. Ono K., Nakane H., Fukushima M., Chermann J.-C., Barre-Sinoussi F. Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases. 1990. Eur. J. Biochem. V. 190. P.469
98. Pauza C.D. 2-LTR cicular viral DNA as a marker for human immunodeficiency vims type 1 infection in vitro. 1994. Virology. V.205. P.470−478
99. Pearson L., Garcia J. A transdominant tat mutant that inhibits tat- induced gene expression from the Human Immunodeficiency Vims Long Terminal Repeats. 1990. Proc. Natl. Acad. Sci. V.87. P.5079−5083
100. Pedersen O.S., Pedersen E.B. Non-nucleoside reverse transcriptase inhibitors: the NNRT1 boom. 1999. Antivir. Chem. Chemother. V.10(6). P.285−314
101. Pettit G.R., Green В., Вомуег W.J. Steroids and related natural products. VI. The structure of a-apoallobetulin. 1961. J. Org. Chem. V.8. P.2879−2883
102. Pi ret В., Legrand.-Poels, S., Sappey €., Piette J. NF-kB transkription factor and Human Immunodeficiency Virus Type 1 (HIV-1) activation by methylene blue photosensitization. 1995. Eur J. Biochemistry. V.228. P.447- 455
103. Ploeger В., Mensinga Т., Sips A., Meulenbelt J., DeJongh• J. A human physiologically-based model for glycyrrhzic acid, a compound subject to presystemic metabolism and enterohepatic cycling. 2000. Pharm. Res. V.12. P. 1516−1525
104. Pluymers W., De Clercq E., Debyser Z. HIV-1 integration as a target for antiretroviral therapy: a review. 2001. Curr. Drug Targets Infect. Disord. V. l (2). P.133−49
105. Plyasunova O.A., Pokrovsky A.G., Baltina L. Design of anti-HIV agents based on glycyrrhizic acid // Abstract book v.2 of Tenth International Conference on AIDS, International Conference on STD, Yokohama, Japan. 1994. P.7−12
106. Pokholok D., Gudima S., Yesipov D., Dobrynin V., Rechinsky V., Kochetkov S. Interactions of the HIV-1 RT AZT-resistant mutant with substrates and AZT-TP. 1993. FEBS Lett. V.325(3). P.237−241
107. Pokholok D., Gudima S., Yesipov D., Dobrynin V., Rechinsky V., Kochetkov S. Interactions of the HIV-1 RT AZT-resistant mutant with substrates and AZT-TP. 1993. FEBS Lett. V.325(3). P.237−241
108. Popov S., Rexach M, Ratner L., Blobel G., Bukrinsky M. Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex. 1998. J. Biol. Chem. V.273(21). P. 13 347−13 352
109. Prichard M.N., Shipman C.h. A three-demensional model to analyze drug-drug interactions. 1990. Antiviral Res. V.14. P. 181−201
110. Pulgar V., Marin O., Meggio F., Allende C.C., Allende J.E., Pinna LA. Optimal sequences for non-phosphate-directed phosphorylation by protein kinase CK1 (casein kinase-l)--a re-evaluation. 1999. Eur. J. Biochem. V.260(2). P.520−526
111. Ren J., Esnouf R, Garman E., Somers D., Ross C., Kirby /., Keeling J., Darby G., Jones 7., Stuart D. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. 1995. Nat. Struct. Biol. V.2(4). P.293−302
112. Res tie Т., Muller В., Goody R.S. RNAseH activiry of HIV-1 reverse transcriptases is confined exclusively to the dimeric forms. 1992. FEBS Lett. V.300. P. 97−100
113. Romero D.L. Advances in development of HIV reverse transcriptase inhibitors. 1994. Ann. Rep. Med Chem. V.29. P. 123−132
114. Suhnel J. Evaluation of synergism or antagonism for the combined action of antiviral agents. 1990. Antiviral Res. V.13. P.23−40
115. Schinazi R.F., C. hu C.K., Babu J.R., Oswald B.J., Saalmam V., Cannon D.L., Eriksson B.F.H., Nasr M. Anthraquinones as a new class of antiviral agents against human immunodeficiency vims. 1990. Antiviral Res. V. 13. P. 265−272
116. SekizaM’a Т., Yanagi K., Itoyama Y. Glycyrrhizin increases survival of mice with herpes simplex encephalitis. 2001. Acta Virol. V.45(l). P.51−54
117. Shibala Sh, Takanashi K., Yano S., Harada M., Saito H., Tamura Y., Kumagai A., Hirabayashi K., Yamamoto M., Nagata N. Chemical modification of glycyrrhetinic acid in relation to the biological activities. 1987. Chem. Pharm. Bull. V.35. P. 19 101 918
118. Shimoyama Y., Ohtaka H., Nagata N., Munakata #., Hayashi N., Ohtsuki K. Physiological correlation between glycyrrhizin, glycyrrhizin-binding lipoxygenase and casein kinase II. 1996. FEBS Lett. V.391. P.238−242.
119. Smith G.P., Petrenko V.A. Phage Display. 1997. Chem.Reviews. V.97. P.391−410
120. Scott J.K., Smith G.P. Searching for Peptide Ligands with an Epitope Library. 1990. Science. V.249. P.386−390
121. Simmonds P., Balfe P., Ludlam C.A., Bishop J.O., Вгом’п A.J. Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1. 1990. J. Virol. V.64(12). P.5840−5850
122. Smith G.P. 1992. Cloning in fuse vector: A laboratory manual. Division of Biological Sciences, Unuversity of Missouiy, Columbia
123. Suhnel J. Evaluation of synergism or antagonism for the combined action of antiviral agents. 1990. Antiviral research. V.13. P.23−40
124. Svinarchuk F.P., Konevetz D.A., Phasunova J.F., Pokrovsty A.G., Vlassov V.V. Inhibition of HIV proliferation in MT4 cells by antisense oligonucleotide conjugated to lipophilic groups. 1993. Biochimie. V. 75. P.243−247
125. Tan G.T., Kinghorn A.D., Hughes S.H., Pezzuto J.M. Psychotrine and its O-methyl ether are selective inhibitors of human immunodeficiency virus-1 reverse transcriptase. 1991. J. Biol. Chem. V.266(35). P.23 529−23 536
126. Tan G.T., Pezzuto J.M., Kinghorn A.D., Hughes S.H. Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 1991. J. Nat. Prod. V.54(l). P.143−54
127. Tarrago-Litvak L., Andreola M.L., Nevinsky G.A., Sarih-Cottin L., Litvak S. The reverse transcriptase of HIV-1: from enzymology to therapeutic intervention. 1994. FASEB J. V.8(8). P.497−503
128. Thomson R.H. Naturally occuring quinones.III. Recent advances. N.Y. Chapman and Hall. 1987. P.732
129. Tochikura T.S., Nakashima H., Yamamoto N. Antiviral agents with activity against human retroviruses. 1989. J. Acquir. Immune Defic. Syndr. V.2(5). P.441−447
130. Quan Y., Motakis D., BuckheitR. Jr., Xu Z.Q., FlavinM.T., PamiakM.A., Wainberg M.A. Sensitivity and resistance to (+)~calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase. 1999. Antivir Ther. V.(4). P.203−209
131. Ugolini S., Mondor .1, Sattentau Q.J. HIV-1 attachment: another look. 1999. Trends Microbiol. V.7(4). P. 144−149
132. Vlietinck A.J., De Bruyne Т., Apers S., Pieters L.A. Plant-derived leading compounds for chemotherapy of human immunodeficiency vims (HIV) infection. 1998. Planta Med. V.64(2). P.97−109
133. Vila J., Walker J.M., It arte E., Weber M.J., Sando J. Phosphorylation of protein kinase С by Casein kinase 1. 1989. FEBS Lett. V.255. P.205−208.
134. WongK., Cantley L.C. Cloning and characterization of a human phosphatidylinositol 4-kinase. 1994. J. Biol. Chem. V.269. P.28 878−28 884
135. Yuan X., Matsuda Z, Matsuda M., Essex M., Lee Т.Н. Human immunodeficiency vims vpr gene encodes a virion-associated protein. 1992. AIDS Res. Hum. Retroviruses. V.6(ll). P. 1265−1271
136. Zhang C.F., Nakamura N., Tewtrakul S., HattoriM., Sun Q.S., Wang Z.Т., Fujiwara T. Sesquiterpenes and alkaloids from Lindera chunii and their inhibitory activities against HIV-1 integrase. 2002. Chem. Pharm. Bull. V.50(9). P. 1195−12 001. ОТ АВТОРА
137. Особая признательность научному руководителю и заведующему лабораторией ретровирусов Покровскому Андрею Георгиевичу, благодаря которому состоялась данная работа.
138. Исследования были выполнены при поддержке грантов Минобразования РФ «Фундаментальные исследования в области естественных наук» и гранта Международного Научного Технического Центра 1198−98.